MeloxicamThird Party Manufacturing in India

Meloxicam is a non-steroidal anti-inflammatory drug belonging to the oxicam class, distinguished by its preferential selectivity for cyclooxygenase-2 over cyclooxygenase-1. It works by inhibiting both COX-1 and COX-2 enzymes, but with a greater inhibitory effect on COX-2, the isoform responsible for the synthesis of pro-inflammatory prostaglandins at sites of inflammation. COX-1 is constitutively expressed in the gastric mucosa, kidneys, and platelets and is responsible for producing protective prostaglandins that maintain mucosal integrity and regulate renal blood flow. By preferentially targeting COX-2, Meloxicam reduces the production of prostaglandins involved in pain, inflammation, and fever while relatively sparing the COX-1-derived prostaglandins that protect the gastrointestinal lining. This pharmacodynamic profile gives Meloxicam a more favourable gastrointestinal safety profile compared to non-selective NSAIDs such as ibuprofen or diclofenac. The drug also inhibits neutrophil activation and reduces the production of inflammatory cytokines, contributing to its anti-inflammatory effect. Meloxicam is well absorbed orally, has a long elimination half-life of approximately 20 hours, and reaches steady-state concentrations within three to five days.

Therapeutic Uses

Meloxicam is prescribed for the treatment of:

• Osteoarthritis: Reduces joint pain, stiffness, and swelling associated with degenerative joint disease, improving mobility and quality of life.
• Rheumatoid arthritis: Controls inflammatory symptoms including morning stiffness, joint tenderness, and swelling in chronic autoimmune arthritis.
• Ankylosing spondylitis: Relieves inflammatory back pain and spinal stiffness in patients with this chronic inflammatory spinal condition.
• Acute musculoskeletal pain: Provides effective short-term relief for sprains, strains, and soft tissue injuries.
• Juvenile idiopathic arthritis: Used in paediatric populations for the management of inflammatory joint disease.

Why Manufacturers Choose Meloxicam

Meloxicam is one of the most widely prescribed NSAIDs globally, valued for its once-daily dosing and improved gastrointestinal safety profile over older NSAIDs. It is available in multiple strengths — 7.5 mg and 15 mg — allowing flexible dosing for different pain severities. The molecule is off-patent, has robust API supply chains in India, and is manufactured using standard tablet compression technology. Its inclusion in the WHO Essential Medicines List and widespread use in both human and veterinary medicine ensures steady year-round demand. Indian manufacturers benefit from strong export opportunities to regulated markets including the US (USP standards), Europe (EP standards), and Asia. This makes Meloxicam one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.